Figure 4.

Plasma concentrations of regorafenib after topical administration of 30 mg ml^–1, 25 μl three times daily in steady state. There was no significant difference between phase I, in which regorafenib was administered by a study nurse to healthy volunteers, and phase II, when patients self‐administered the eye drops. Data presented as box‐plots (median, boxes 25th and 75th percentile; whiskers 10th and 90th percentile; single values outside 10th and 90th percentile). DREAM, Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration